---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-058749"
form_type: "8-K"
ticker: "MIST"
cik: "0001408443"
company_name: "Milestone Pharmaceuticals Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T03:54:01.673492+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Milestone Pharma Q1 operating loss $15M; etripamil NDA on track for Q3 2023

## Summary
- Cash of $101M as of March 31, 2023; with $125M RTW financing, runway into mid-2025.
- NDA submission for etripamil (PSVT) to FDA remains on track for Q3 2023.
- Phase 2 ReVeRA trial (AFib-RVR) topline data expected H2 2023.
- Appointed Seth H.Z. Fischer to Board of Directors in March 2023.
- Operating loss of $15.0M in Q1 2023 vs. $14.0M in Q1 2022; R&D expense rose to $10.3M.

## SEC filing metadata
- accession: 0001104659-23-058749
- form_type: 8-K
- ticker: MIST
- cik: 0001408443
- company_name: Milestone Pharmaceuticals Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1408443/000110465923058749/0001104659-23-058749-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1408443/000110465923058749/tm2315317d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-058749
- JSON: https://secwatch.observer/filing/0001104659-23-058749.json
- Plain text: https://secwatch.observer/filing/0001104659-23-058749.txt

## Key facts
- Earnings Releases
  Milestone Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2023.
  - Period: the first quarter ended March 31, 2023
  - Result: reported results
  source text: On May 11, 2023, Milestone Pharmaceuticals Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2023, which also provided a clinical and corporate update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1408443/000110465923058749/0001104659-23-058749-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.